HC Wainwright Has Positive Outlook for ZVRA FY2026 Earnings

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) – Investment analysts at HC Wainwright upped their FY2026 EPS estimates for shares of Zevra Therapeutics in a note issued to investors on Thursday, August 6th. HC Wainwright analyst B. Folkes now expects that the company will post earnings of $0.57 per share for the year, up from their previous estimate of $0.55. HC Wainwright has a “Buy” rating and a $26.00 price objective on the stock. The consensus estimate for Zevra Therapeutics’ current full-year earnings is $0.56 per share. HC Wainwright also issued estimates for Zevra Therapeutics’ Q4 2026 earnings at $0.13 EPS.

Zevra Therapeutics (NASDAQ:ZVRA) last announced its earnings results on Wednesday, August 5th. The company reported $0.25 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.11 by $0.14. The company had revenue of $39.66 million for the quarter, compared to the consensus estimate of $33.88 million. Zevra Therapeutics had a net margin of 42.82% and a return on equity of 58.95%.

Several other equities research analysts also recently issued reports on the company. Citigroup reissued an “outperform” rating on shares of Zevra Therapeutics in a research note on Thursday. Guggenheim lowered their target price on Zevra Therapeutics from $29.00 to $24.00 and set a “buy” rating on the stock in a research note on Monday, July 27th. BTIG Research dropped their target price on Zevra Therapeutics from $27.00 to $24.00 and set a “buy” rating on the stock in a report on Monday, July 27th. Citizens Jmp increased their price target on shares of Zevra Therapeutics from $25.00 to $28.00 and gave the stock a “market outperform” rating in a research report on Thursday. Finally, Cantor Fitzgerald raised their price target on shares of Zevra Therapeutics from $24.00 to $34.00 and gave the stock an “overweight” rating in a report on Monday, June 8th. Nine research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat.com, Zevra Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $27.29.

Zevra Therapeutics Stock Up 12.8%

Shares of Zevra Therapeutics stock opened at $11.88 on Friday. Zevra Therapeutics has a 12 month low of $7.16 and a 12 month high of $15.03. The stock has a market cap of $702.35 million, a PE ratio of 12.91 and a beta of 0.91. The business has a fifty day simple moving average of $12.32 and a 200-day simple moving average of $10.57.

Institutional Investors Weigh In On Zevra Therapeutics

A number of large investors have recently bought and sold shares of ZVRA. Gunpowder Capital Management LLC dba Oliver Wealth Management acquired a new position in Zevra Therapeutics during the fourth quarter worth $53,000. Russell Investments Group Ltd. boosted its stake in shares of Zevra Therapeutics by 235.7% during the 3rd quarter. Russell Investments Group Ltd. now owns 6,374 shares of the company’s stock worth $61,000 after acquiring an additional 4,475 shares in the last quarter. Tower Research Capital LLC TRC boosted its stake in shares of Zevra Therapeutics by 617.5% during the 2nd quarter. Tower Research Capital LLC TRC now owns 9,937 shares of the company’s stock worth $88,000 after acquiring an additional 8,552 shares in the last quarter. Creative Planning acquired a new position in shares of Zevra Therapeutics during the 2nd quarter valued at about $92,000. Finally, Quarry LP acquired a new position in shares of Zevra Therapeutics during the 3rd quarter valued at about $103,000. 35.03% of the stock is currently owned by institutional investors.

More Zevra Therapeutics News

Here are the key news stories impacting Zevra Therapeutics this week:

• Positive Sentiment: Q2 earnings and revenue exceeded expectations. Zevra reported $39.7 million in second-quarter revenue, up 53% year over year and above the roughly $34 million consensus estimate. EPS of $0.25 also surpassed analyst expectations of approximately $0.08–$0.11. MIPLYFFA generated $30.2 million in revenue, supporting the company’s commercial growth. Zevra Therapeutics Q2 earnings article
• Positive Sentiment: Cash generation and financial flexibility improved. The company reported a strong cash position of $260.2 million and positive operating execution, giving it additional resources to support MIPLYFFA commercialization and future development programs. Zevra Q2 2026 financial results and corporate update
• Positive Sentiment: Regulatory and patent updates strengthened the MIPLYFFA outlook. Zevra expects a European Commission CHMP reexamination opinion in the fourth quarter, while MIPLYFFA’s Orange Book listing has been extended to 2041. The developments may improve visibility around potential European approval and provide longer U.S. market exclusivity. Zevra CHMP reexamination and Orange Book update
• Positive Sentiment: Citizens JMP raised its price target to $28 from $25 and maintained a “market outperform” rating. The new target is well above the recent trading level and reinforces bullish analyst sentiment; several analysts have targets in the mid-$20s to mid-$30s. Benzinga analyst price target report
• Neutral Sentiment: Institutional positioning was mixed, with some funds adding shares and others reducing or exiting positions. This suggests continued disagreement about Zevra’s valuation and execution outlook.
• Negative Sentiment: Recent insider activity showed sales by executives and no reported insider purchases over the past six months. While these transactions do not necessarily reflect business fundamentals, they may temper investor enthusiasm.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome.